Related Experiment Video
Updated: Jan 13, 2026
03:23
Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
Published on: May 10, 2024
1.3K
Rituximab and Intravenous Immunoglobulin (IVIG) for Refractory Eosinophilic Fasciitis: A Case Report
Maryam Sahebari1, Motahhareh Karimoddini2, Naser Tayyebi Meibodi3
1Rheumatic Diseases Research Center, Mashhad University of Medical Sciences Mashhad Iran.
Clinical Case Reports
|January 7, 2026
Summary
Eosinophilic fasciitis (EF) is a rare condition. A case study found rituximab and IVIG improved EF in a patient resistant to standard treatments, suggesting a potential new therapy.
Area of Science:
- Rheumatology
- Immunology
- Dermatology
Background:
- Eosinophilic fasciitis (EF) is a rare, idiopathic connective tissue disorder.
- EF presents with inflammation and thickening of the fascia, leading to pain and stiffness.
- Standard treatments for EF include corticosteroids and immunosuppressants, with variable success.
Purpose of the Study:
- To report a case of eosinophilic fasciitis refractory to conventional therapies.
- To evaluate the efficacy of rituximab and intravenous immunoglobulin (IVIG) in a treatment-resistant EF case.
Main Methods:
- A case study of a 40-year-old male patient with diagnosed eosinophilic fasciitis.
- The patient had failed to respond to standard EF treatments.
- Treatment with rituximab and IVIG was administered.
Main Results:
- The patient showed significant clinical improvement after receiving rituximab and IVIG.
- Symptoms such as pain, stiffness, and skin thickening markedly reduced.
- No major adverse events were reported during the treatment period.
Conclusions:
- Rituximab and IVIG may be effective therapeutic options for refractory eosinophilic fasciitis.
- Further clinical trials are warranted to establish the efficacy and safety of this treatment regimen.
- This case highlights potential novel therapeutic avenues for rare autoimmune conditions.
